BROADCASTS.com

Editing genes to fix genetic mutations could revolutionize how we treat disease, but gene editing research is only in early stages, and plenty still needs to learned before we know it's safe for widespread use. 

In this episode of Limelight Alpha's Talking Stocks, 7Investing Lead Advisor, Maxx Chatsko, joins Todd Campbell to explains the pros and cons of gene editing. The duo discuss:

\n
• How gene editing, including CRISPR Cas, compares to RNAi therapies; 
\n
• What gene editing companies are furthest along in their research; 
\n
• What data is on tap from leading gene editing stocks, including Crispr Therapeutics, Editas Medicine, Caribou Biosciences, and Intellia Therapeutics, and
\n
• What could go wrong in gene editing drug development, including risks associated with double-strand breaks.
\n

You can learn more about 7Investing here: https://7investing.com/subscribe/?referred_by_id=747

You can learn more about Limelight Alpha here: https://seekingalpha.com/author/limelight-alpha-management-partners/research

Follow Limelight Alpha on Twitter: @AlphaLimelight

Follow Maxx Chatsko on Twitter: @7MaxxChatsko